US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
Year: 2025
Type: article
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-25-00663
Authors: Suparna Wedam, Preeti Narayan, Haley Gittleman, Joyce Cheng, Vishal Bhatnagar, Hairat Sabit, Lauren S.L. Price, Nam Atiqur Rahman, Haw-Jyh Chiu, Nikolett Biel, Tiffany Ricks, Mallorie Fiero, Shenghui Tang, Christy Osgood, William Pierce, Richard Pazdur, Paul G. Kluetz, Laleh Amiri-Kordestani
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413420021